Heron Therapeutics, Inc. (NASDAQ:HRTX) CFO Ira Duarte Buys 85,000 Shares

Heron Therapeutics, Inc. (NASDAQ:HRTX) CFO Ira Duarte acquired 85,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $0.89 per share, with a total value of $75,650.00. Following the completion of the transaction, the chief financial officer now owns 85,000 shares of the company’s stock, valued at approximately $75,650. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Heron Therapeutics Price Performance

Shares of HRTX traded up $0.14 during mid-day trading on Friday, reaching $1.06. The company had a trading volume of 6,397,622 shares, compared to its average volume of 2,266,309. The company’s 50-day moving average is $0.87 and its 200-day moving average is $1.27. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.41. The company has a market capitalization of $158.85 million, a P/E ratio of -1.05 and a beta of 1.12.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The firm had revenue of $31.76 million during the quarter, compared to the consensus estimate of $31.75 million. Heron Therapeutics had a negative net margin of 97.45% and a negative return on equity of 21,127.62%. As a group, equities analysts expect that Heron Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. bought a new position in Heron Therapeutics in the 2nd quarter valued at $38,000. Jacob Asset Management of New York LLC boosted its position in shares of Heron Therapeutics by 22.3% in the 1st quarter. Jacob Asset Management of New York LLC now owns 326,657 shares of the biotechnology company’s stock worth $493,000 after purchasing an additional 59,629 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Heron Therapeutics by 85.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 58,935 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 27,223 shares in the last quarter. Searle & CO. lifted its holdings in Heron Therapeutics by 90.2% during the first quarter. Searle & CO. now owns 63,250 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Monaco Asset Management SAM bought a new position in Heron Therapeutics during the second quarter worth about $470,000. 81.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on HRTX shares. Needham & Company LLC decreased their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.